WuXi AppTec Co., Ltd. Class A Stock 12‑Month Price Target Raised to CNY 164.73, Implies 28% UpsideTradingView·2 hours ago02359+10.56%603259+10.00%
05:49 ETWuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Modelprnewswire·16 hours ago02359+10.56%603259+10.00%
WUXI APPTEC Interim Net Profit RMB11.08B, Up 33.7% YoY; Interim DPS RMB0.51AASTOCKS News·16 hours ago02359+10.56%603259+10.00%
WuXi AppTec declares 2026 mid-year dividend of RMB 5.1 per 10 sharesPUBT·16 hours ago02359+10.56%603259+10.00%
METIS TECHBIO-P AI Formulation Platform Secures Localized Deployment at HENGRUI PHARMAAASTOCKS News·21 hours ago07666+0.56%01276+1.59%
Metis TechBio to Deploy AI Formulation Platform at Hengrui PharmaceuticalsTip Ranks·21 hours ago07666+0.56%01276+1.59%
Jiangsu Hengrui files HKEX next-day disclosure return reporting share repurchase at RMB 52.96PUBT·17 hours ago01276+1.59%600276+1.09%
A-Share Three Major Indices Open 0.2%-1.5% Higher; APPTEC Jumps 7%AASTOCKS News·29 minutes ago02359+10.56%600721+10.00%
Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit ForecastsAASTOCKS News·Jul 26 at 10:29 PM01276+1.59%600276+1.09%
Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin AnalogTip Ranks·Jul 29 at 09:38 AM01276+1.59%600276+1.09%
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line UseTip Ranks·Jul 23 at 07:37 AM01276+1.59%600276+1.09%
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatmentPUBT·Jul 23 at 07:32 AM01276+1.59%600276+1.09%
As weight-loss drug orders surge, global funds pile into China’s WuXi AppTecSCMP·Jul 24 at 05:39 AM02359+10.56%603259+10.00%
China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New HighAASTOCKS News·Jul 20 at 01:00 AM510660+2.30%159992+3.14%
WuXi AppTec joins FTSE4Good Index Series for fourth straight yearPUBT·Jul 21 at 06:54 PM02359+10.56%603259+10.00%
